PATENT CLAIM ANALYSIS

Application Number: 15875532
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "145100"]

Abstract:
The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Claim (Index 23):
The method of  claim 14 , wherein the cancer is selected from the group consisting of melanoma, lung cancer, cutaneous squamous cell carcinoma, colorectal cancer, breast cancer, ovarian cancer, head and neck cancer, hepatocellular carcinoma, urothelial cancer, and renal cell carcinoma.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 86.0
- Lexical Diversity: 1.26316
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14227733', '15649373', '14547026', '14270750', '14383602']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7562727169155609
- 35 USC 102 Novelty (BERT): 0.5329074735600343
- Combined Prediction Score: 0.7339361925800083
- Mean Citation Score: 356.9909
- Max Citation Score: 363.25638
- Similarity Product: 249.4245941036868

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test